Immunotherapy for Genitourinary Cancers: New Opportunities for Clinical Impact

Urol Clin North Am. 2020 Nov;47(4):xi-xii. doi: 10.1016/j.ucl.2020.08.001.

Authors

Sujit S Nair¹, Ashutosh K Tewari²

Affiliations

¹ Department of Urology, Icahn School of Medicine at Mount Sinai, Annenberg 24-15, New York, NY 10029, USA. Electronic address: Sujit.nair@mountsinai.org.
² Department of Urology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, One Gustave L. Levy Place, Box 1272 L6-57, New York, NY 10029, USA. Electronic address: Ash.tewari@mountsinai.org.

PMID: 33008502
DOI: 10.1016/j.ucl.2020.08.001

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
Humans
Immunotherapy* / methods
Urogenital Neoplasms / drug therapy
Urogenital Neoplasms / immunology
Urogenital Neoplasms / therapy*

Substances

Antineoplastic Agents, Immunological